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1 Preface/working process 
Autumn 2015, my study friend Mathilde Bjørnerem and I contacted Sveinung Wergeland 
Sørbye to discuss potential topics for our master thesis. We were both interested in studying 
topics such as gynecology and/or women’s cancer, and more specifically HPV and cervical 
cancer.  In the following 3-4 weeks, we got several articles to read, discuss and evaluate. This 
to get a deeper understanding in how the screening program works, the development of 
cancer and what topics had been studied earlier.  
 
We were introduced to Finn-Egil Skjeldestad, who would later be our main supervisor. Finn 
Egil was a close collaborator of Sveinung, had vast experience in analyzing/programming in 
statistical programs such as SPSS, and had been supervising these kinds of tasks several 
times before. In September 2015, the four of us had our first meeting and started to discuss 
the further progress. Mathilde and I wanted a common overall theme, though separate 
objectives, to be able to discuss and help guide each other along the way.  We were included 
in a group of 3 other students, Liv Reidun Tverrelv, Marte Slettbakk and Kristina Benedicte 
Dahl Olafsen. In October of our 4th year we prepared a project plan, which included the 
background material that would later constitute the background section of the final thesis. It 
was a continuous process of writing, discussion and getting feedback both by mail and 
through personal meetings with the supervisors.  
 
In January 2016, we started having regular literature evaluation meetings every other week 
to present new articles. The articles evaluated then, were more related to our individual 
objectives and were going to constitute a collection of our main resources. This process was 
very educational in that I feel I got a more critical eye on studies done, and how to evaluate 
whether results are trustworthy or not. Additionally, I benefited greatly from the discussions 
in the group and questions considering interpretation of the results from both supervisors.  
In total, we had 5-6 literature evaluation meetings. A first draft of the plan for analysis was 




We continued the work for a couple of weeks in August 2016, before we headed off to fifth 
years clinicals. At this point we got introduced to the data file including the whole study 
population in SPSS. Finn Egil and I had two meetings during the fall, whereas I continuously 
sent him new drafts of the thesis for feedback.  
 
From March to June 2017, most of the writing and programming was done. Tables and 
diagrams were made by me based on statistical analysis done by Finn Egil. The analyses were 
done based on my analytical plan. Results and discussion were then written with continuous 
feedback from my supervisor. Throughout the whole process, we had regular contact by 
mail and several meetings in Tromsø. I want to thank my main supervisor Finn-Egil 
Skjeldestad and co-supervisor Sveinung Wergeland Sørbye for a good cooperation. They 
have contributed with years of knowledge in the field, and have given words of 
encouragement when the final product seemed out of reach. The next step is to reform my 
master thesis into an article and to get our study published in a national-or international 
journal.  
  
Line Linea Kaasa  
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Objectives: To assess compliance based on screening recommendations and outcome of 
screening for women diagnosed with an unsatisfactory pap-smear compared to normal 
controls.  
 
Setting: An eight-year prospective cohort study performed on women in Troms and 
Finnmark participating in the national screening program for cervical cancer from 2006-
2014. 
 
Material and methods: We assessed compliance before and after an index pap-smear. 
Women in the exposed cohort were defined as compliant 1 through 6 months or non-
compliant >7 months. Women in the non-exposed cohort were defined as too early (<24 
months), compliant (24 through 41) or too late (>42months). We identified status within 1st 
screening period (42 months after index smear) and calculated the detection rate.  Main 
outcomes were CIN2, CIN3 and SCC. The women’s most adverse outcome was estimated 
within 78 study months. Used in the study are chi-square test, t-test and survival analysis in 
SPSS with level of significance p < 0.05.   
 
Results: 1,571 exposed women and 24,665 non-exposed women were included in the study.  
The exposed women were less compliant prior to index compared to the control group 
(41.9% vs 56.3%). Of the non-exposed women 31.7% met within the recommended interval 
for their first follow-up. The compliant, exposed women accounted for 51.0%. The detection 
rate of CIN2, CIN3 and ICC was significantly higher within the exposed women. A total of 
1.3% CIN2+ in the exposed women and 0.2% in the non-exposed women were detected 
within the first screening period. Within final follow-up 2.0% and 0.8% CIN2+ were found in 
the exposed and non-exposed groups respectively.  
 
Conclusion: Women with unsatisfactory tests are more compliant to recommended 
guidelines and have, in our low-risk population, higher incidence of CIN2+ compared to 





3.1 The cervical cancer screening program 
Worldwide, cervical cancer is the third and fourth most common cancer considering 
incidence and mortality. (1) Every year, 60 000 women in Europe die of cervical cancer, 70-
80 of these in Norway. (2) Many cervical cancer cases can be prevented by routine screening 
with pap-smear examinations. Based on this, a national screening program was established. 
In 1995 “The cervical cancer screening program” was launched, recommending pap-smear 
screening every third year for women between 25 and 69 years of age. (3) (4) The main aim 
of the program is to discover premalignant lesions (cervical dysplasia), and treat them before 
they develop into cancer. (4) 
 
The program’s success depends on the screening population; the women and their 
compliance to the recommended guidelines. Women being “lost-to-follow-up” is a problem.  
Although physicians and pathologists are the ones who collect, forward and analyze the 
samples, an optimal screening process also depends on the compliance of the women to 
recommended follow-up guidelines. Pap-smears that are not of satisfactory quality, called 
unsatisfactory tests, require closer follow-up with more frequent testing than normal 
smears.  If the women do not follow the recommended follow-up regimen, this may result in 
delayed diagnosis, and the risk of losing women with “need-to-treat-dysplasia” along the 
way. 
 
3.2 Cervical dysplasia 
Approximately 400,000 pap smears are taken every year in Norway. 25,000 of these are 
classified as unsatisfactory or abnormal (with cervical dysplasia). (4) Cervical dysplasia, which 
is seen within the cells, is the morphological sign that there is an ongoing inflammatory low 
grade squamous intraepithelial lesion (LSIL) or a transforming process, a high grade 
squamous intraepithelial lesion (HSIL).  Cervical dysplasia is almost exclusively a result of 
infection or transformation by human papillomavirus (HPV). (5) (6) More than 80% of 
sexually active women and men will once or several times during their lifetime become 
infected by the HPV virus. (7) Approximately 90% of infections will heal on their own over 
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the course of 6-24 months. The remaining 10 % of HPV-infections could persist and pose risk 
of high-grade lesions and development of cancer. (8, 9) Considering that HPV is the 
underlying factor in most cases of cervical cancer (10-14); detection and treatment of early 
cervical dysplasia, caused by HPV, may prevent further development toward cancer. (15) 
Dysplastic lesions are classified according to morphological changes (Bethesda 2001). (16) 
The classification is based partly on the relationship between cytoplasm and nucleus, as well 
as the cell’s ability to absorb color. Lesions are classified as following:  
Normal  
ASC-US: Atypical squamous cells of undetermined significance  
LSIL: Low grade squamous intraepithelial lesion 
ASC-H: Atypical squamous cells, whereas HSIL cannot be excluded 
HSIL: High grade squamous intraepithelial lesion.  
In 2011 approximately 3% (>12,000) of pap-smears were classified as unsatisfactory. (4) 
According to the Bethesda criteria a minimal squamous cellularity is required for the test to 
qualify as satisfactory. If a conventional smear contains less than 8000 well-visualized 
squamous cells, and a liquid-based preparation less than 5000, the specimen adequacy is 
considered poor. (16) These samples are not suitable for diagnostics and the woman is asked 
to return for a new smear.  
 
3.3 Follow-up 
Of the 13,000 annual abnormal (ASC-US+) pap-smears, the largest share contains low-grade 
lesions. (4) Women with abnormal pap-smears are followed until the smear is normal or 
they are diagnosed with treatment-requiring dysplasia (CIN2+). What ought to be done with 
the distinctive results is determined by risk estimation. Due to this, the recommended 
guidelines for follow-up of cervical-cytological screening tests (17) are based on a principle 
of equal management of equal risk for high grade lesions/cervical cancer. (18-20)  
 
If the woman’s test is normal, she continues in the screening program at 3 years’ interval. 
The cancer registry sends out a reminding letter if the woman has not attended after 42 
months. A woman whose test is unsatisfactory is recommended to have a new pap-smear 
within 1-3 months. If the cervical dysplasia is classified as high grade (ASC-H or HSIL), the 
woman should be referred directly to colposcopy and biopsy. Between these two extremes 
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is follow-up of low-grade dysplasia. If the pap-smear shows ASC-US or LSIL, the woman is 
recommended a delayed triage, with a new pap- and HPV test after 6-12 months.  
The remaining material of the liquid based pap-test is HPV tested because of the virus’ close 
relation to development of CIN2+. (21) Studies have shown a 3-fold increase in CIN2+ risk in 
women with LSIL and positive HPV compared to women with LSIL and a negative HPV test. 
(19) Women with repeated ASC-US/LSIL and positive HPV test are referred to colposcopy 
and biopsy. Women with ASC-H/HSIL at delayed triage are also referred to colposcopy and 
biopsy, independent of HPV test outcome. Women with a normal pap-smear and negative 
HPV test, as well as women with repeated ASC-US/LSIL and negative HPV-test, are all 
recommended further follow-up at a 3-year interval.  
 
When the doctor performs a colposcopy, the cervical mucosa is examined in order to 
evaluate the severity of the dysplasia. Simultaneously, the doctor takes biopsies which are 
sent to a pathologist who performs a histological examination in a microscope. The 
histological samples are studied considering the different tissues and to what degree the 
dysplasia extends from the basement membrane towards the surface. Biopsies taken of 
cervical dysplasia are categorized as CIN1, CIN2 and CIN3 in increasing severity according to 
the extent to which the epithelium is replaced by dysplastic cells. The preinvasive lesions are 
categorized as CIN1 (low grade lesions - await treatment), where the cells involve the first 
third of the epithelium. CIN2 involve two thirds of the cervical epithelium and CIN3 (high 
grade lesions) involve the full thickness of the epithelium. The basement membrane is intact 
in all three pre-cancerous classifications. Both CIN2 and CIN3 are further managed identically 
and are therefore categorized as CIN2+. If the biopsy shows CIN2+, the woman is 
recommended surgical treatment; conization, in which the area with dysplasia is removed. If 
the basement membrane is infiltrated or destroyed by malignant epithelial cells, the 
dysplasia has evolved into invasive cancer. 
 
3.4 Participation in the screening program 
Despite efficient ways of screening, an 80% national coverage is reached after two 
reminders over five years. (4) In Norway, 50 % of cervical cancers occur among women in 
the non-participating group. Of women with unsatisfactory pap-smears, 62% show up for a 
recommended follow-up smear within 12 months. (4) A woman with consecutive 
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unsatisfactory results is advised to return for new pap-smear testing shortly after. Several 
follow-ups within a short period of time, without any precise answers on whether she has 
cervical dysplasia or not, could make the woman tired and increase the risk of further non-
participation (“lost to follow-up”).  
 
3.5 Previous studies  
By now, there are only a few studies done based specifically on the unsatisfactory pap- 
smear. The main focus of these studies has been causes of unsatisfactory tests, typically 
which factors are most likely to contribute (22, 23). Results have shown that scant cellularity 
is the most common cause (95.7%) of an unsatisfactory pap-smear. (22) Other reasons are 
obscuring inflammation, blood, foreign material, endometrial cells, poorly fixed material or 
low squamous component. In addition, the authors have focused on whether patients with 
unsatisfactory tests have any factors in common. Unsatisfactory tests were according to 
Alsharif et al more likely to appear in older patients and were more frequent in menopausal 
women, post hysterectomy, and post hysterectomy with radiation and/or chemotherapy for 
malignancy. (22) Aspects considering other characteristics than age will not be further 
discussed in the present study.  
 
Some earlier studies are based on follow-up and development of CIN2+, specifically among 
women with unsatisfactory tests compared to women with normal tests. (3, 22-24)  Alsharif 
et al found that the group with unsatisfactory tests had a higher proportion of abnormal 
follow-up pap-smears, as well as higher incidence of CIN1+. However, the study population 
is of small (278-cases and 284 controls) sample size with little statistical power. 
Furthermore, these patients are only followed up for 24 months, and not the full 
recommended 3-year screening period. This may have given a lower rate of follow-up pap 
testing and biopsies in the control group, thereby probably influencing the final results to 
show a higher proportion of abnormalities in the unsatisfactory group. 
 
A historical prospective cohort of women in the USA studied clinical factors associated with 
compliance after an unsatisfactory pap-smear. (23) Though to my knowledge, neither this, 
nor other previous studies have assessed compliance in different aspects such as both 
before and after the index smear. Furthermore, there are few studies that have discussed 
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the context of compliance and outcome; regarding both in single follow-up testing and in 
total risk estimation of development of CIN2+ during the whole study period.  
 
4 Objectives 
In a cohort design I aim to compare compliance with screening recommendations and 
outcome of screening for women diagnosed with an unsatisfactory smear compared to 
women who have normal smears.  
 
5 Material and methods  
5.1 Study population 
The Department of Clinical Pathology, University Hospital of North-Norway, Tromsø, 
receives pap-smears from women in Troms and Finnmark county. Each year approximately 
22-25,000 cervical smears and histological samples are analyzed and added to a clinical 
database (SymPathy). Within this database, we created a cohort study and identified women 
with an unsatisfactory smear during 01.01.2006 through 31.12.2011 as exposed women, 
while women with a normal smear during 01.01.2006 through 31.12.2007 where defined as 
non-exposed women. Follow-up ended 31.12.2014. 
 
From 1991 through 2011, 481,857 women were registered with 523,620 pap-smears. We 
utilized the screening history of eligible study participants to define our final study 
population. Among 31,770 eligible non- exposed women and 2,203 exposed women, we 
excluded women with a previous history of CIN1 or higher, women with a history HSIL or 
higher, and women whose last smear prior to index were abnormal (Figure 1). After these 
exclusions, the final study population comprised 1,571 exposed women and 24,665 non-
exposed women.  
 
5.2 Outcomes 
In our analysis, we had two main outcomes- compliance to recommended guidelines and 




Compliance was assessed in two aspects from most recent to index smear (background 
compliance) and from index to 1st follow-u smear (study compliance). Background 
compliance was categorized as too short (less than 24 months), within interval (24 through 
41 months), and too late (> 42 months) or no previous specimen collection (index smear was 
1st smear). Participants that did not have any follow-up after index smear were defined as 
the “non-attender” category in study compliance. For the control cohort, study compliance 
was defined as too short if the specimen was collected less than 24 months after index 
smear, within interval at 24 through 41 months’ range, and too late when collection took 
place 42 months or later after index smear. For exposed women, compliance was too early 
(less than 1 month), within interval 1-6 months and too late if the smear was taken 7 months 
or later after an index smear. Age was categorized in three groups (25-39, 40-54-55-69 
years). 
 
We identified “status within 1st screening period” (< 42 months) and calculated the 
detection rates of CIN2, CIN3 and cervical cancer (CC). Finally, we estimated the women’s 
most adverse outcome within 78 study months (two screening rounds).  
 
5.3 Statistical methods 
Used in the study are chi-square test, t-test and survival analysis in SPSS with level of 
significance p < 0.05.   
 
5.4 Formal approvals 
The Regional Committee for Medical and Health Research Ethics, North Norway, has 
evaluated the protocol as a quality assurance study, fulfilling the requirements for data 
protection procedures within the department (2015/1795/REK Nord). Norwegian regulations 
exempt quality assurance studies from written informed consent from the patients.  The 










A higher proportion of the women with unsatisfactory index test were recruited from the 
first versus the second time period (61.8 % vs 38.2%). Furthermore, exposed women were 
significantly younger than non-exposed women in the control cohort.  Study population 
characteristics are displayed in table 1.  
 
Compared to the control cohort, a larger proportion of the exposed women had no previous 
smear collected (15.4% vs 7.3%). In addition, a higher proportion of the women in the 
exposed group had too long or too short interval from most recent to index smear, meaning 
they were less compliant compared to the control cohort (Table 1).  
 
14.4% in the control group and 10.4% in the exposed group had no smear collected after 
their index smear. The women in the non-exposed cohort were significantly less compliant 
to the recommended guidelines compared to the exposed women, respectively 31.7% vs 
51.0% (Table 2).  Regardless of age, the exposed women were more compliant than the non-
exposed women.  
 
By first screening period, a higher proportion of the exposed women returned to screening, 
while a higher proportion in the non-exposed group had incomplete follow-up (Table 3, 
Column A).  A total of 54 CIN2+ (0.2 %) among the non-exposed women and 20 CIN2+ (1.3 
%) in the exposed women were diagnosed within first 42 months. In both groups, most cases 
were diagnosed on indication, as follow-up after an abnormal smear. A higher percentage of 
CIN2 was found in the exposed group (0.6%) compared to the non-exposed group (0.1%). 24 
(0.1 %) and 8 (0.5 %) cases of CIN3 were diagnosed among non-exposed and exposed 
women, respectively. Within first screening period, three cervical cancers were diagnosed, 2 
(0.2%) in the exposed women and 1 (0.0%) in the non-exposed women. The difference in 
proportion of diagnostic cases of CIN2, CIN3 and CC in the two groups was highly significant 
(p<0.01).   
 
Within 2nd screening round, a higher proportion of the exposed women returned to regular 
screening compared to the non-exposed women (Table 3, column B). At this point, 42.3% of 
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women in the control group still had incomplete follow-up compared to 23.9% of the 
exposed group.  
 
 At 78 months, a total of 101 CIN2 (0.4 %), 100 CIN3 (0.4%) and 10 CC (0.0%) were diagnosed 
in the non-exposed women. In the exposed women 11 CIN2 (0.7 %), 17 CIN3 (1.1 %) and 3 
CC (0.2 %), were diagnosed. This accounted for an overall higher percentage of diagnosed 
cases in the exposed group compared to the non-exposed group. Our results show an 
increasing cumulative incidence of CIN2+. The difference in cumulative incidence between 
the two cohorts increases over time. (Figure 2, survival analysis) The cumulative incidence 
among exposed women were significantly higher at 24, 42 and 78 months compared to the 
control cohort. (Table 4) 
 
The women diagnosed with cervical cancer were young, all below 60 years of age. Most of 
























In our study, women with unsatisfactory pap-smear, regardless of age, were significantly 
more compliant to recommended guidelines compared to women with normal index smear. 
We observed an increasing compliance with increasing age in both groups. Of the non-
compliant women, most met too late. A total of 54 CIN2+ (0.2 %) in the non-exposed women 
and 20 CIN2+ (1.3 %) in the exposed women were diagnosed within first screening period. Of 
these, the cumulative incidence of both CIN2, CIN3 and CC was higher among exposed 
women, compared to the non-exposed women. Within 78 month, a total of 211 CIN2+ cases 
(0.8 %) were diagnosed in the non-exposed women, compared to 21 CIN2+ cases (2.0 %) in 
the exposed women. (p<0.001).  
 
While a previous Norwegian study (24) did not assess compliance with follow-up after an 
unsatisfactory smear, two studies from the US (22, 23) estimated compliance with different 
windows for compliant follow-up. Owen’s et al evaluated follow-up within 120 days in 
agreement with the recommendations from the American Cancer Association and within 24 
months. They found that 53.4% of women with unsatisfactory pap-smears had a follow-up 
within recommended window, and a total of 80% within a two years’ period. Additionally, 
their results show that women aged 50+ were more likely to meet within 120 days for a 
follow-up smear, compared to women below 50 years of age (57.2% vs 48.8%). These results 
are equivalent to ours with a satisfactory compliance of 51.0 % as well as our increased 
compliance with increasing age.  
 
Alsharif et al reported compliance within a 24- months window and found a much lower 
compliance in the control group compared to the unsatisfactory study group, respectively 
22.5% vs 65.1% (22). Similar findings are reported from a previous Norwegian study 
estimating follow-up rates to 83.7% and 40.7 % in the exposed and non-exposed women, 
respectively (24).   
 
To my knowledge, our study is first to differentiate between too early/too late show-up 
when assessing compliance to recommended screening interval. While Owen’s et al do not 
distinguish between “no follow-up” and “non-compliant” women when estimating overall 
rates of CIN2+, Alsharif et al estimate CIN2+ rates only among women who have a follow-up. 
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Nygård et al have, similar to our study, included women with “no follow-up” in their analysis 
of CIN2+.  
 
Both Alsharif, Owens and Nygård have assessed CIN2+ within a two-year period. CIN2/3 and 
ICC develops over time, and one would question whether 24 months is sufficient to make an 
estimate of CIN2+ occurrence.  Nevertheless, Alsharif's results at 24 months show a CIN2+ 
risk of 1.8% in the exposed group and 0.35% in the control group.  
 
Owens et al utilizes two control groups for women with unsatisfactory smears. (23) One 
control group comprised women with all satisfactory smears after excluding those with a 
history of HSIL, endocervical adenocarcinoma in-situ, squamous cell carcinoma and other 
cervical malignancy, while the other control group consisted of all women with a valid 
cytological diagnosis. Within a two-year’s follow-up a total of 10 CIN2+ were diagnosed, of 
these 8 within 120 days. Their results implicate no increase in CIN2+ development in women 
with unsatisfactory smear, compared to either control groups. However, the short follow-up 
time and the low number of outcomes makes this study invalid for any comparison to other 
studies.  
 
Nygård’s study is most comparable to ours. As Nygård et al, we excluded women with 
previous HSIL+, CIN1+ and abnormal test on the most recent before index. These exclusions 
make both populations low-risk populations for assessment of CIN2+.  
 
Because the recommended follow-up of unsatisfactory- and normal smears differs greatly in 
compliance interval, assessment done prior to 40 months will be invalid based on the high 
percentage incomplete follow-up in the non-exposed women. An ideal comparison of 
exposed and non-exposed women should therefore be follow-up through two screening 
rounds, which equals 78 months. To my knowledge, no other study than the study from the 
Norwegian Cancer registry (24) have this long-term follow-up. Women with no histologically 
verified CIN2/3 or ICC within 2 years’ follow-up, were in Nygård’s study followed an 
additional 5 years, compared to our 42 months and additional 3 years (36 months). Their 
results implicate a hazard rate of being diagnosed with CIN2/3 after an unsatisfactory test 
during the long-term follow-up as 1.2 (95% CI: 1.04-1.45) compared to the control group. 
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They do not display numbers of cumulative incidence in long term-follow up. Their results 
are slightly lower than ours, but highly comparable. Within our 78 months of follow-up, a 
total 2% had CIN2+ as most adverse outcome compared to a 0.8% in the control group of 
women with normal smears.   
 
Today’s guidelines are based upon risk estimation and the principle of “equal management 
of equal risk”. Katki et al (11, 20) based their thresholds on cumulative incidence of CIN3+ 
within 5 years after a negative co-test (negative pap-smear combined with a negative HPV 
test). They calculated risk of CIN3+ for all possible combinations of the co-test, and 
benchmarked it to the already established risk thresholds for pap-alone to further suggest 
adequate management. E.g. all women with results that equals a five year CIN3+ risk of 2.6% 
are recommended to have a follow-up smear within 6-12 months and women with results 
equaling a 5-year CIN3+ risk of 0,26% are sent back to regular screening with 3-years 
interval.   
 
The CIN3+ risk at 78 months in our study was 1.3% in the exposed women, a lower risk than 
what, according to the risk-thresholds (20), would implicate a new pap-smear within few 
months. In our study, a negative smear prior to index was a requirement. However, it has 
not been performed systematically HPV testing, and we thereby do not have data to 
consider HPV results in our analysis. Thus, we could further not calculate risk of CIN3+ 
development based on the unsatisfactory pap-smear in combination with the HPV test.  
 
In clinical practice the recommended guidelines are not as strictly practiced as in a clinical 
register-based study. Intervals are shortened and extended both by the woman herself, but 
also by the practitioner who’s performing the testing. Our study show that 51% of exposed 
women are compliant to recommended guidelines, a percentage of coverage that is not 
satisfying.  
 
Starting March 2015, 4 counties introduced HPV testing in primary screening. It is further 
discussed use of the HPV test in residual material from the unsatisfactory smear, to decide if 
the woman can be returned to regular screening (HPV negative) or if she needs a follow-up 
smear (HPV positive). This would make it possible to estimate a more accurate risk at first 
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unsatisfactory smear, instead of having the woman returning for several smears before she 
gets a diagnose. Fewer unnecessary follow-up consultations might increase the compliance 
among the women with unsatisfactory pap-smears. In addition, using HPV test in primary 
screening will also reduce the number of unsatisfactory smears because only HPV positive 
samples are triaged by cytology. Future studies should include consistent HPV-testing at 
each visit during assessment of unsatisfactory smear, in order to settle management 
regimens for follow-up.  
 
Our study adds to the literature in several ways. Few previous studies done have as large 
study population of women with unsatisfactory tests who are followed up long-term basis. 
Because of our population-based study design, the results reflect clinical practice within the 
Norwegian cervical screening program. An ideal study would be performed as a randomized 
two-arm study with HPV test in one arm, and pap-smears as the other. All testing should 
additionally be done by a selected group of practitioners who were all trained in the same 
standards of analyzing and further management. 
 
In our study, we present numbers of a low risk population. As expected the overall incidence 
of cancer is low, but significantly higher in the exposed women compared to the non-
exposed. In the exposed women, three cancers were diagnosed. One diagnosed within three 
months as follow-up of an unsatisfactory index. Two of the cervical cancers were diagnosed 
in follow-up of symptoms, with normal smears as most recent. Thus, the three occurring 
cancers in our exposed cohort cannot be acquired to the unsatisfactory pap smear itself. The 
cancers are rather cases of coincidental occurrence, which no screening program can one 












We observed a significantly higher compliance among exposed women compared to a non-
exposed cohort.  Additionally, our study shows a significantly higher cumulative incidence of 
CIN2+ at all months measured in the group of women with unsatisfactory smears. 
Nevertheless, the incidence is low in both groups. Based on the overall low cancer risk in the 
population, we question the necessity of such short intervals in today’s recommendations 
for women with unsatisfactory pap-smears. However, our study population is too small to 
make a statement on cancer risk in women with unsatisfactory pap-smears. Further 
recommendations for follow-up should be calculated based on studies with adequate long-
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Criteria of exclusion 
 
Exposed cohort  
 
N n  n N 
31,770    2,203 
 1,991 Age ≤ 24 år 256  
 1,277 Age ≥ 70 år 67  
28,502    1,880 
 653 ≥ CIN1 before index 47  
 359 ≥ HSIL before index 31  
 1,417 ≥ HSIL før/≥ CIN1 before index 95  
26,073    1,707 
 475 Unsatisfactory as last smear 
before index.   
46  
 782 ASCUS as last smear before index.   67  
 151 LSIL as last smear before index.   23  
     






























































P < 0.001 
 
Background compliance 
No previous smear 
Too short interval 
Within interval 



















10.4 Table 2 – Compliance from index test to first follow-up by cohort 
 








N = 24,665 N = 1,571 
% % 
No follow-up 14.4 10.4  
 
P < 0.001 
No compliance 
- Too early 












10.5 Table 3 – Status of follow-up at 42 and 78 months by cohort 
 




N = 24,665 N = 1,571 









No follow-up 14.4 14.4 10.4 10.4 















































10.6 Table 4 – Cumulative incidence of CIN2+ at 24, 41 and 78 months by cohort 
 
 Control cohort 
Cumulative incidence (95% CI) 
Exposed cohort 
Cumulative incidence (95% CI) 
24 months 0.12 (0.07-0.17) 1.1 (0.5-1.7) 
42 months 0.4 (0.3-0.5) 2.1 (1.2-3.0) 













































Time from index to 
diagnose 
(months) 
Most recent smear  
prior cancer diagnosis 
Non-exposed cohort 53 3 After symptoms/normal smear 
Non-exposed cohort 33 38 Follow-up of abnormal smears 
Non-exposed cohort 56 38 Follow-up of abnormal smears 
Non-exposed cohort 37 44 Incomplete follow-up of previous smear 
Non-exposed cohort 34 45 Incomplete follow-up of previous smear 
Non-exposed cohort 38 50 Incomplete follow-up of previous smear 
Non-exposed cohort 29 57 Incomplete follow-up of previous smear 
Non-exposed cohort 35 67 Incomplete follow-up of previous smear 
Non-exposed cohort 37 70 Incomplete follow-up of previous smear 
Non-exposed cohort 48 74 Incomplete follow-up of previous smear 
Exposed-cohort 49 4 Follow-up of an unsatisfactory smear  
Exposed cohort 31 33 After symptoms/normal smear 
Exposed cohort 39 78 After symptoms/normal smear 


















11 Summary of outcomes in own study compared to main articles 




Alder < 25 og > 69 år 
Abnormal test som siste prøve før 
index 
Tidligere HSIL+ og/eller CIN1+  
 




Ihh til retningslinjene 
Eksponert 51,0% 
Ikke eksponert: 31,7% 
Innen første screening 
Eksponert: 1,3 % 
Ikke eksponert: 0,2% 
Innen siste oppfølging.  
Eksponert 2,0 % 




Kvinner med tidligere cervikal cancer 
eller total hysterektomi.  
Resultater fra konvensjonelle 
celleprøver.  
Alder < 21 og >65 




- A: 250366 
- B: 249718  
Oppfølging innen 120d  
53,4% (varierte mellom 41,1-65,6%) 
Innen 2 år: 80% 
Assosiasjoner til oppfølging 
Kvinner < 50 vs >50: 57,2 % vs 48,8% 
+ HPV vs ingen HPV: 84,6% vs 53,9 %   
- HPV vs ingen HPV: 42,1% vs 53,9 % 
CIN 2+ etter uegnet prøve: 
Totalt 10  
(8 innen 120 d,2 med tidl CIN2+) 
HR 0,91 (0,50-1,7) – kontrollgruppe A 
HR 1,2 (0,63-2,1) – kontrollgruppe B 




Uegnede prøver som ikke ble 
prosessert. 
Gjentatte uegnede prøver fra kvinner 
som allerede var med i studien.  
Unormale prøver som ASC-US, LSIL, 
HSIL+ 4 uegna for evaluering  





Ny test innen 24 mnd: 
Kasus: 65,1%  
Kontroll: 22,5% 
Forekomst CIN 2+: 
Kasus:  1,80 %  




CIN2/3 eller ICC mellom 1.jan 1990 og 
indexprøven. 
Indexprøve ASCUS, LSIL, HSIL, ICC.  
Abnormal prøve som siste før index. 
Celleprøve ila de 6 mnd før 
indexprøven.   





2 års oppfølging 
Kasus: 83,6% 
Kontroll: 40,7 % 
 
2 års oppfølging, CIN2+ 
Kasus: 0,6%   
Kontroll: 0,21% 
Langtidsoppfølging, CIN2+ 
Kasus: 191 kvinner HR 1,2 (ref norm 
prøve) 
 
